Trial Profile
Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary) ; Hepatitis B vaccine
- Indications Hepatitis B
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 23 Oct 2013 Accrual to date is 93% according to United Kingdom Clinical Research Network.
- 12 Sep 2013 Accrual to date is 68% according to United Kingdom Clinical Research Network.
- 01 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.